Corvus reports Q3 net loss $6.0M, cash $32.2M; soquelitinib Phase 3 trial protocol finalized

Corvus Pharmaceuticals, Inc.

2023-Q3 EPS reported -$0.43

Net loss $6.0M vs $14.8M in Q3 2022; R&D expenses down to $4.0M from $10.4M.
Cash, equivalents and marketable securities $32.2M as of Sept 30, 2023 (Dec 31, 2022: $42.3M).
ATM program raised $7.8M net from 2.46M shares; FY 2023 cash burn guidance $22-23M.
Soquelitinib Phase 3 registrational trial for relapsed PTCL protocol finalized; enrollment expected Q2 2024; Phase 2 in RCC planned early 2024.
New soquelitinib data accepted for ASH Dec 2023; preclinical autoimmune/allergy data published.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Corvus Pharmaceuticals, Inc. reported the third quarter ended September 30, 2023 results: net income The net loss for the three months ended September 30, 2023 was $6.0 million.

Period: the third quarter ended September 30, 2023
Net income: The net loss for the three months ended September 30, 2023 was $6.0 million
Result: reported results

Exact text from the filing

Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Corvus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-006818

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.